The present application relates to a novel immunity-inducing agent for treating and/or preventing cancer. Specifically, the present invention provides an immunity-inducing agent that contains a recombinant vector as an active ingredient, said recombinant vector comprising: at least one polypeptide that has immunological reactivity and that is selected from among MCEMP1-derived polypeptides and variants thereof； or a polynucleotide that encodes the polypeptide. The recombinant vector is capable of expressing the polypeptide within a living body. Also provided is an immunity induction method that includes administering the immunity-inducing agent to a subject.
